Loading...
XNAS
LIVN
Market cap2.50bUSD
Jun 26, Last price  
45.80USD
1D
-0.15%
1Q
17.05%
Jan 2017
1.85%
IPO
-28.60%
Name

LivaNova PLC

Chart & Performance

D1W1MN
XNAS:LIVN chart
No data to show
P/E
39.49
P/S
1.99
EPS
1.16
Div Yield, %
—
Shrs. gr., 5y
2.45%
Rev. gr., 5y
2.94%
Revenues
1.25b
+8.66%
103,442,570123,441,575130,968,437121,229,742143,600,979167,775,672190,464,398218,502,731254,320,417282,014,160291,557,9981,213,900,0001,012,300,0001,107,000,0001,084,200,000934,200,0001,035,400,0001,021,800,0001,153,545,0001,253,437,000
Net income
63m
+260.39%
-12,218,348-59,069,192-51,180,107-10,334,76526,720,62078,448,88446,725,71036,077,73246,357,50254,890,25757,847,534-62,800,000-25,100,000-189,400,000-155,500,000-343,300,000-135,700,000-86,200,00017,546,00063,234,000
CFO
183m
+144.33%
-3,969,672-70,876,209-20,688,85614,455,20724,589,95042,885,48649,872,10775,026,16579,053,75954,195,81679,675,11690,200,00091,300,000120,500,000-91,100,000-79,400,000102,500,00069,900,00074,914,000183,038,000
Earnings
Jul 29, 2025

Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
URL
https://www.livanova.com/en-us
IPO date
Oct 19, 2015
Employees
2,900
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,253,437
8.66%
1,153,545
12.89%
1,021,800
-1.31%
Cost of revenue
565,078
576,112
470,400
Unusual Expense (Income)
NOPBT
688,359
577,433
551,400
NOPBT Margin
54.92%
50.06%
53.96%
Operating Taxes
25,058
(98,876)
11,100
Tax Rate
3.64%
2.01%
NOPAT
663,301
676,309
540,300
Net income
63,234
260.39%
17,546
-120.35%
(86,200)
-36.48%
Dividends
Dividend yield
Proceeds from repurchase of equity
(8,439)
(7,503)
(8,700)
BB yield
0.33%
0.27%
0.29%
Debt
Debt current
87,044
26,473
23,400
Long-term debt
638,874
659,319
577,100
Deferred revenue
3,874
Other long-term liabilities
193,362
191,454
229,826
Net debt
271,976
396,445
370,000
Cash flow
Cash from operating activities
183,038
74,914
69,900
CAPEX
(47,107)
(34,981)
(26,500)
Cash from investing activities
(48,160)
(40,331)
(38,400)
Cash from financing activities
18,551
21,484
280,100
FCF
879,108
281,299
484,500
Balance
Cash
428,858
266,504
214,200
Long term investments
25,084
22,843
16,300
Excess cash
391,270
231,670
179,410
Stockholders' equity
(983,420)
(911,834)
(949,725)
Invested Capital
3,173,813
3,021,320
2,945,525
ROIC
21.41%
22.67%
19.72%
ROCE
31.27%
27.22%
27.51%
EV
Common stock shares outstanding
54,574
54,212
53,472
Price
46.31
-10.49%
51.74
-6.84%
55.54
-36.47%
Market cap
2,527,322
-9.90%
2,804,929
-5.55%
2,969,835
-32.91%
EV
2,799,298
3,201,374
3,339,835
EBITDA
739,503
638,289
609,200
EV/EBITDA
3.79
5.02
5.48
Interest
63,070
58,853
48,300
Interest/NOPBT
9.16%
10.19%
8.76%